908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors

908 Devices Inc. announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors due to the company’s strategic refocus on public health, safety and defense tech. These changes are effective immediately.

Previously, Dr. Vann was Performing the Duties of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs and was Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense at the DoD. In this capacity she was the principal advisor on nuclear weapons, nuclear energy, chemical and biological defense programs, chemical demilitarization, and treaty management. From September 2019 through January 2022, she served as Deputy Assistant Secretary of Defense for Chemical and Biological Defense.

Dr. Vann also held positions at the Defense Threat Reduction Agency (DTRA), part of the DoD, including Chief of the Advanced and Emerging Threats Division from 2017 to 2019, where she led efforts for the characterization of advanced and emerging chemical and biological threats. She also served in other capacities at DTRA including Chief of the Detection and Diagnostics Systems Development Branch and Chief of the Assays and Biomarkers Branch.

“I’m thrilled to welcome Brandi to our Board of Directors. I’ve had the privilege of knowing her for many years, dating back to the founding of 908 Devices, and have always valued her insight,” said Kevin J. Knopp, CEO and Co-founder, 908 Devices. “Her many years of leadership in CBRN detection enhances the strategic counsel of our board as we navigate opportunities in national security and global preparedness.”

“I’m honored to join the 908 Devices Board of Directors and to support its leadership team as they continue their mission to equip military personnel and first responders with field-ready devices that rapidly identify chemical threats,” said Dr. Vann. “I’ve admired the company’s innovation and impact, and I’m excited to contribute to its important work in defense tech.”

“Brandi’s government experience and expertise in nuclear, chemical, and biological defense should be helpful as we shape and execute our strategy for commercializing advanced chemical detection devices,” said Kevin Hrusovsky, chairman of 908 Devices. “We also thank Jeff for his many contributions on our Board, including as chair of our compensation committee. He played an important role in helping shape our bioprocessing strategy and divestiture. We are grateful for his thoughtful, strategic perspective and leadership.”